Welcome to another impactful episode of The OncoAlert Weekly Roundup — your go-to source for the latest breakthroughs in oncology, hosted by Gil Morgan.

🚨 This week, we’re diving deep into where precision meets practicality — from genomic tools redefining risk in breast and lung cancer, to combination therapies setting new standards, and even exercise as a tool in metastatic prostate cancer.

🧬 Highlights include:

• Groundbreaking data on HER2DX and ctDNA in early-stage cancer
• Long-term FLAURA2 results showing improved survival in EGFR-mutant NSCLC
• A compelling review on the anti-cancer potential of exercise in advanced prostate cancer
• The science behind epithelial–mesenchymal transition (EMT) and why it matters now more than ever

💡 Whether you're a clinician, researcher, or cancer care advocate, this week’s roundup gives you the insights you need to stay ahead in the rapidly evolving world of oncology.

👇 Don’t forget:
✅ Subscribe for weekly updates
📬 Sign up for our newsletter: www.oncoalert360.com
📢 Share with colleagues & join the conversation in the comments
🔔 Hit the bell so you never miss an update